文献速递妇科肿瘤

2020-99年181个国家扩大人乳头瘤病毒疫苗接种和宫颈筛查的影响及全球消除宫颈癌的潜力:一项模型研究

Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
PubMed 文献 · Lancet Oncol · 2019-02-19

该建模研究基于高质量肿瘤登记数据,使用Policy1-Cervix模拟平台预测2020-69年全球宫颈癌负担。

要点

  • 联合干预可使中HDI国家发病率在2065-69年降至6/10万以下。
  • 低HDI国家本世纪末仍无法全部达到4/10万以下。

核心结论

  • 快速实现高覆盖疫苗接种可在三四十年后显著减轻疾病负担,但近期效果需对未受益于疫苗的老年队列提供筛查。

研究设计与样本

  • 统计趋势分析和建模研究,使用国际癌症研究机构发布的《五大洲癌症发病率》系列高质量肿瘤登记数据。
  • 使用经过全面验证的模拟平台Policy1-Cervix进行动态多队列建模分析,预测未来发病率和负担。
  • 数据按全球、人类发展指数(HDI)类别和单个国家层面呈现。

主要发现

  • 从2020年起快速扩大联合高覆盖筛查和疫苗接种,平均年宫颈癌发病率降至6/10万以下的时间为:极高HDI国家2045-49年、高HDI国家2055-59年、中HDI国家2065-69年、低HDI国家2085-89年。
  • 降至4/10万以下的时间为:极高HDI国家2055-59年、高HDI国家2065-69年、中HDI国家2070-79年、低HDI国家2090-2100年或更晚;本世纪末并非所有低HDI国家都能达到4/10万以下。

关键数值与推荐

  • 快速扩大情景:2020年前全球疫苗接种覆盖率达80-100%,使用广谱HPV疫苗。
  • 筛查情景:所有LMICs在35岁和45岁各进行一次HPV筛查,全球覆盖率70%。
  • 逐渐扩大情景:2030年疫苗接种覆盖率20-45%、一生一次筛查覆盖率25-70%,2050年升至疫苗接种40-90%、一生一次筛查90%(按HDI类别平均覆盖率)。
  • 逐渐扩大情景下,本世纪末平均宫颈癌发病率为:极高HDI国家0.8/10万、高HDI国家1.3/10万、中HDI国家4.4/10万、低HDI国家14/10万。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cervical screening and human papillomavirus (HPV) vaccination have been implemented in most high-income countries; however, coverage is low in low-income and middle-income countries (LMICs). In 2018, the Director-General of WHO announced a call to action for the elimination of cervical cancer as a public health problem. WHO has called for global action to scale-up vaccination, screening, and treatment of precancer, early detection and prompt treatment of early invasive cancers, and palliative care. An elimination threshold in terms of cervical cancer incidence has not yet been defined, but an absolute rate of cervical cancer incidence could be chosen for such a threshold. In this study, we aimed to quantify the potential cumulative effect of scaled up global vaccination and screening coverage on the number of cervical cancer cases averted over the 50 years from 2020 to 2069, and to predict outcomes beyond 2070 to identify the earliest years by which cervical cancer rates could drop below two absolute levels that could be considered as possible elimination thresholds-the rare cancer threshold (six new cases per 100 000 women per year, which has been observed in only a few countries), and a lower threshold of four new cases per 100 000 women per year. METHODS: In this statistical trends analysis and modelling study, we did a statistical analysis of existing trends in cervical cancer worldwide using high-quality cancer registry data included in the Cancer Incidence in Five Continents series published by the International Agency for Research on Cancer. We then used a comprehensive and extensively validated simulation platform, Policy1-Cervix, to do a dynamic multicohort modelled analysis of the impact of potential scale-up scenarios for cervical cancer prevention, in order to predict the future incidence rates and burden of cervical cancer. Data are presented globally, by Human Development Index (HDI) category, and at the individual country level. FINDINGS: In the absence of further intervention, there would be 44·4 million cervical cancer cases diagnosed globally over the period 2020-69, with almost two-thirds of cases occurring in low-HDI or medium-HDI countries. Rapid vaccination scale-up to 80-100% coverage globally by 2020 with a broad-spectrum HPV vaccine could avert 6·7-7·7 million cases in this period, but more than half of these cases will be averted after 2060. Implementation of HPV-based screening twice per lifetime at age 35 years and 45 years in all LMICs with 70% coverage globally will bring forward the effects of prevention and avert a total of 12·5-13·4 million cases in the next 50 years. Rapid scale-up of combined high-coverage screening and vaccination from 2020 onwards would result in average annual cervical cancer incidence declining to less than six new cases per 100 000 individuals by 2045-49 for very-high-HDI countries, 2055-59 for high-HDI countries, 2065-69 for medium-HDI countries, and 2085-89 for low-HDI countries, and to less than four cases per 100 000 by 2055-59 for very-high-HDI countries, 2065-69 for high-HDI countries, 2070-79 for medium-HDI countries, and 2090-2100 or beyond for low-HDI countries. However, rates of less than four new cases per 100 000 would not be achieved in all individual low-HDI countries by the end of the century. If delivery of vaccination and screening is more gradually scaled up over the period 2020-50 (eg, 20-45% vaccination coverage and 25-70% once-per-lifetime screening coverage by 2030, increasing to 40-90% vaccination coverage and 90% once-per-lifetime screening coverage by 2050, when considered as average coverage rates across HDI categories), end of the century incidence rates will be reduced by a lesser amount. In this scenario, average cervical cancer incidence rates will decline to 0·8 cases per 100 000 for very-high-HDI countries, 1·3 per 100 000 for high-HDI countries, 4·4 per 100 000 for medium-HDI countries, and 14 per 100 000 for low-HDI countries, by the end of the century. INTERPRETATION: More than 44 million women will be diagnosed with cervical cancer in the next 50 years if primary and secondary prevention programmes are not implemented in LMICs. If high coverage vaccination can be implemented quickly, a substantial effect on the burden of disease will be seen after three to four decades, but nearer-term impact will require delivery of cervical screening to older cohorts who will not benefit from HPV vaccination. Widespread coverage of both HPV vaccination and cervical screening from 2020 onwards has the potential to avert up to 12·5-13·4 million cervical cancer cases by 2069, and could achieve average cervical cancer incidence of around four per 100 000 women per year or less, for all country HDI categories, by the end of the century. A draft global strategy to accelerate cervical cancer elimination, with goals and targets for the period 2020-30, will be considered at the World Health Assembly in 2020. The findings presented here have helped inform initial discussions of elimination targets, and ongoing comparative modelling with other groups is supporting the development of the final goals and targets for cervical cancer elimination. FUNDING: National Health and Medical Research Council (NHMRC) Australia, part-funded via the NHMRC Centre of Excellence for Cervical Cancer Control (C4; APP1135172).

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Simms KT, Steinberg J, Caruana M, et al. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study. Lancet Oncol. 2019. PMID: 30795950. doi:10.1016/S1470-2045(18)30836-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。